Zoladex 3.6 mg, syringe applicator implant

Zoladex® is a synthetic analog of natural gonadotropin-releasing hormone (GnRH). With constant use, the drug Zoladex® inhibits the release of luteinizing hormone (LH) by the pituitary gland, which leads to a decrease in the concentration of testosterone in the blood serum in men and the concentration of estradiol in the blood serum in women. This effect is reversible after discontinuation of therapy. At the initial stage, Zoladex®, like other GnRH agonists, can cause a temporary increase in serum testosterone concentrations in men and serum estradiol concentrations in women. In the early stages of Zoladex® therapy, some women may experience vaginal bleeding of varying duration and intensity.
In men, by about 21 days after the introduction of the first implant, testosterone concentrations decrease to castration levels and remain reduced with continuous treatment, carried out every 28 days in the case of Zoladex® 3.6 mg or every 3 months in the case of Zoladex® 10.8 mg . Such a decrease in the concentration of testosterone against the background of the use of the drug Zoladex® 3.6 mg in most patients leads to regression of the prostate tumor and to symptomatic improvement.
In women, serum estradiol concentration also decreases by about 21 days after the introduction of the first implant of the drug Zoladex® 3.6 mg and, with regular administration of the drug every 28 days, remains reduced to a level comparable to that observed in menopausal women. This reduction leads to a positive effect in hormone-dependent forms of breast cancer, endometriosis, uterine fibroids and suppression of the development of follicles in the ovaries. It also causes thinning of the endometrium and is the cause of amenorrhea in most patients.
After administration of Zoladex® 10.8 mg, serum estradiol concentration in women decreases within 4 weeks after the introduction of the first implant and remains reduced to a level comparable to that observed in menopausal women. With the initial use of other GnRH analogues and the transition to the drug Zoladex® 10.8 mg, suppression of estradiol levels is maintained. Suppression of estradiol levels leads to a therapeutic effect in endometriosis and uterine fibroids.
Zoladex® 3.6 mg in combination with iron preparations has been shown to cause amenorrhea and an increase in hemoglobin and relevant hematological parameters in women with uterine fibroids and concomitant anemia.
Against the background of taking GnRH agonists in women, the onset of menopause may occur. Rarely, some women do not return to menstruation after the end of therapy.

Composition

Indications

Contraindications

Side effects

Interaction

How to take, course of administration and dosage

Overdose

Special Instructions